Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.665
+0.145 (9.54%)
Nov 4, 2026, 5:25 PM CET
STO:NEWBRY Balance Sheet
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Cash & Equivalents | 9.34 | 14.56 | 15.3 | 8.53 | 33.33 |
Cash & Short-Term Investments | 9.34 | 14.56 | 15.3 | 8.53 | 33.33 |
Cash Growth | -35.83% | -4.84% | 79.44% | -74.42% | 153.59% |
Accounts Receivable | - | 7.06 | 15.24 | 9.12 | 0 |
Other Receivables | 25.24 | 14.17 | 7.01 | 6.39 | 0.79 |
Receivables | 25.24 | 21.23 | 22.25 | 15.51 | 0.79 |
Inventory | 12.86 | 9 | 5 | 2.11 | 1.77 |
Prepaid Expenses | - | 1.67 | 1.42 | 1.09 | 0.58 |
Total Current Assets | 47.45 | 46.46 | 43.97 | 27.24 | 36.47 |
Goodwill | - | 0.34 | 1.26 | 2.13 | 3.04 |
Other Intangible Assets | 28.73 | 30.55 | 45.64 | 43.55 | 47.39 |
Total Assets | 76.18 | 77.35 | 90.87 | 72.92 | 86.91 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Accounts Payable | - | 7.32 | 1.94 | 4.28 | 2.04 |
Accrued Expenses | - | 4.46 | 6.28 | 3.19 | 0.89 |
Current Income Taxes Payable | - | 0.35 | 0.08 | 0.16 | 0.18 |
Current Unearned Revenue | - | - | - | 1.63 | - |
Other Current Liabilities | 55.95 | 18.72 | 21.14 | 2.52 | 2.96 |
Total Current Liabilities | 55.95 | 30.85 | 29.45 | 11.77 | 6.06 |
Other Long-Term Liabilities | 0.61 | 3.75 | 9.51 | 11.77 | 12.08 |
Total Liabilities | 56.56 | 34.6 | 38.95 | 23.54 | 18.14 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Common Stock | 19.62 | 0.97 | 0.77 | 0.62 | 0.62 |
Additional Paid-In Capital | - | 121.9 | 106.72 | 88.71 | 88.71 |
Comprehensive Income & Other | - | -80.12 | -55.58 | -39.96 | -20.57 |
Shareholders' Equity | 19.62 | 42.75 | 51.92 | 49.38 | 68.77 |
Total Liabilities & Equity | 76.18 | 77.35 | 90.87 | 72.92 | 86.91 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 |
Net Cash (Debt) | 9.34 | 14.56 | 15.3 | 8.53 | 33.33 |
Net Cash Growth | -35.83% | -4.84% | 79.44% | -74.42% | 153.59% |
Net Cash Per Share | 0.31 | 0.56 | 0.71 | 0.44 | 1.87 |
Filing Date Shares Outstanding | 30.4 | 30.4 | 24.26 | 19.52 | 19.52 |
Total Common Shares Outstanding | 30.4 | 30.4 | 24.26 | 19.52 | 19.52 |
Working Capital | -8.5 | 15.61 | 14.53 | 15.47 | 30.42 |
Book Value Per Share | 0.65 | 1.41 | 2.14 | 2.53 | 3.52 |
Tangible Book Value | -9.11 | 11.87 | 5.02 | 3.7 | 18.34 |
Tangible Book Value Per Share | -0.30 | 0.39 | 0.21 | 0.19 | 0.94 |